LENVAT 4MG CAPS 30'S

About

Lenvatinib is a multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4, platelet-derived growth factor receptor (PDGFR) alpha, KIT, and RET proto-oncogene. By inhibiting these receptor tyrosine kinases, lenvatinib impedes tumor angiogenesis, tumor growth, and other oncogenic signaling pathways. It is an oral medication primarily used in the treatment of various advanced cancers.

Its broad spectrum of kinase inhibition makes it effective in targeting multiple pathways involved in cancer progression, including those responsible for cell proliferation and survival. This mechanism of action contributes to its therapeutic utility in challenging malignancies where other treatments may have failed or are not suitable. Regular monitoring for adverse effects and dose adjustments are crucial during treatment.

Uses

• Treatment of differentiated thyroid cancer (DTC) that is refractory to radioactive iodine.
• Management of advanced renal cell carcinoma (RCC) in combination with everolimus.
• First-line treatment for unresectable hepatocellular carcinoma (HCC).
• Treatment of advanced endometrial carcinoma in combination with pembrolizumab.

Directions For Use

Take orally once daily, with or without food, as directed by your physician. Swallow the capsule whole; do not open or crush.

Benefits

• Effective in slowing tumor progression in various advanced cancers.
• Offers a targeted approach to cancer therapy.
• Improves progression-free survival in several indications.
• Oral administration provides convenience for patients.
• Can be used as a first-line or subsequent therapy.
• Addresses multiple pathways involved in cancer growth.

Side Effects

• Hypertension
• Fatigue
• Diarrhea
• Arthralgia/Myalgia
• Decreased appetite
• Nausea
• Proteinuria
• Weight loss
• Headache
• Vomiting
• Palmar-plantar erythrodysesthesia syndrome
• Stomatitis

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects or interact with the medication.
• Pregnancy - Lenvatinib is contraindicated in pregnancy due to potential fetal harm. Effective contraception must be used during treatment and for at least one month after the last dose.
• Breastfeeding - Breastfeeding is not recommended during treatment with lenvatinib and for at least one week after the last dose, due to the potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary for moderate to severe impairment, and liver function should be monitored regularly.
• Kidney - Use with caution in patients with renal impairment. Dose adjustments may be required for moderate to severe impairment, and renal function should be closely monitored.
• Lung - Monitor for signs of pulmonary embolism or other lung-related adverse events, though direct lung toxicity is less common.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.